LAUSR

Gastrointestinal (GI) cancers represent a major global health burden, significantly impacts the digestive system. Recent research has focused on the relationship between interleukin‐6 (IL‐6), interleukin‐10 (IL‐10), and C‐reactive protein (CRP) to deepen understanding of GI cancer—including esophageal, gastric, pancreatic, hepatobiliary, and colorectal cancers—pathogenesis and to enhance diagnostic and therapeutic strategies. Elevated levels of IL‐6, IL‐10, and CRP have been associated with advanced disease stages and poor prognosis, underscoring their potential utility as biomarkers for disease progression and outcome prediction. Moreover, these markers appear to modulate the sensitivity of GI cancer cells to chemotherapy, suggesting that their assessment in serum and tissue samples could aid therapeutic decision‐making and predict treatment responses. In addition to their diagnostic and prognostic value, IL‐6, IL‐10, and CRP are being investigated as targets for preventive strategies. These findings highlight the potential role of anti‐inflammatory interventions in chemoprevention. Overall, studying the interplay among IL‐6, IL‐10, and CRP has yielded valuable insights into the molecular mechanisms driving GI cancer development and progression. Continued research is essential to fully elucidate these complex interactions and to translate these findings into effective clinical applications for the management of GI malignancies.